REPOSITIVE LIMITED: INTERNATIONAL DEVELOPMENT PROGRAMME TO INCREASE THE IMPACT OUR ONLINE PLATFORM FOR QUERYING AND ACCESS TO MOLECULAR DATA ON PATIENT DERIVED XENOGRAFT MODELS.

REPOSITIVE LIMITED：国际开发计划，旨在提高我们在线平台的影响力，用于查询和访问患者衍生异种移植模型的分子数据。

• 批准号: 132556
• 金额: $ 2.67万
• 依托单位: REPOSITIVE LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132556
• 关键词: REPOSITIVE; LIMITED; INTERNATIONAL; DEVELOPMENT; PROGRAMME

Patient derived xenograft (PDX) models are powerful tools used by scientists studying cancer and indiscovery of new cancer treatments. Each one is grown from a sample of a cancerous tumour donated by acancer sufferer: so they are precious, valuable and useful. But scientists find it hard to find suitable onesfor their work and so many spend a lot of time testing them, just to collect the same basic information overand over again. Repositive is creating an online platform for scientists to find PDX models and data tomake sure that they are the best ones for their work. This project, costing £29,968 and lasting 3 months,funds us build the platform with the help of PDX model providers and pharmaceutical companies who usethem often, and who will give us feedback on our concepts and designs. It will save 3 months ofdevelopment time and will enable us to make sure that they find the platform valuable and use it when itis completed. In future it will help companies to save up to 6 months in drug discovery time, so that newtreatments can be identified and brought to market more quickly and at lower cost than now.

患者来源的异种移植(PDX)模型是科学家研究癌症和发现新的癌症治疗方法所使用的强大工具。每一个都是从癌症患者捐赠的癌症肿瘤样本中生长出来的：所以它们是珍贵的、有价值的和有用的。但科学家们发现很难找到适合他们工作的工具，所以许多人花了大量时间测试它们，只是为了一遍又一遍地收集相同的基本信息。RePositive正在为科学家创建一个在线平台，以找到PDX模型和数据，以确保它们是适合他们工作的最佳模型。这个项目耗资29,968 GB，持续3个月，资助我们在PDX模型提供商和制药公司的帮助下建立平台，他们经常使用PDX模型，并将就我们的概念和设计向我们提供反馈。它将节省3个月的开发时间，并将使我们能够确保他们认为该平台有价值，并在完成后使用它。未来，它将帮助公司节省最多6个月的药物发现时间，以便能够更快地识别新疗法并将其推向市场，而且成本比现在更低。